Psychopharmacological Interventions in Major Depressive Disorder
Summary
Major depressive disorder (MDD) affects a substantial proportion of the global population and is characterised by persistent low mood, anhedonia and cognitive dysfunction. Pharmacotherapy remains the cornerstone of treatment, with first-line agents including selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline reuptake inhibitors (SNRIs). These compounds act on monoaminergic pathways to alleviate core symptoms, yet many patients exhibit partial response or residual cognitive and emotional deficits. In recent years, multimodal antidepressants such as vortioxetine have emerged, targeting multiple serotonin receptor subtypes to enhance neurotransmitter balance and cognitive outcomes. Rapid-acting interventions, notably N-methyl-D-aspartate (NMDA) receptor antagonists, have demonstrated efficacy in treatment-resistant cases. Efforts to personalise treatment through pharmacogenetic profiling and biomarker identification aim to reduce latency to response and improve tolerability. Overall, ongoing innovation seeks to optimise efficacy, minimise side effects and address domains of function beyond mood alone.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Psychopharmacological Interventions in Major Depressive Disorder publication trend
The graph below shows the total number of articles in psychopharmacological interventions in major depressive disorder across all publications each year (not limited to Nature Index journals).
Technical terms
Selective Serotonin Reuptake Inhibitor (SSRI): An antidepressant that increases synaptic serotonin by inhibiting its reuptake into presynaptic neurons.
Serotonin–Noradrenaline Reuptake Inhibitor (SNRI): An agent that elevates levels of both serotonin and noradrenaline by blocking their reuptake transporters.
N-methyl-D-aspartate (NMDA) receptor antagonist: A compound that modulates glutamatergic neurotransmission by inhibiting NMDA receptor activity, often used for rapid antidepressant effects.
Anhedonia: A core symptom of MDD, defined as a diminished ability to experience pleasure or interest in normally enjoyable activities.
Cognitive dysfunction: Impairments in mental processes such as attention, memory and executive function often persisting after mood symptoms improve.
References
- Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. EClinicalMedicine (2024).
- The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. The International Journal of Neuropsychopharmacology (2016).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.